{{위키데이터 속성 추적}}
{{Infobox drug
| drug_name =
| INN               =
| type              = <!-- empty -->
| image                 = Pirfenidone2DACS.svg
| width                 = 150
| alt                   =
| Verifiedfields        = changed
| verifiedrevid         = 417788348

<!-- Clinical data -->
| pronounce         =
| tradename             = Esbriet, Pirespa, Etuary 등
| Drugs.com             = {{drugs.com|monograph|pirfenidone}}
| MedlinePlus           = a615008
| licence_EU            = yes
| DailyMedID            = Pirfenidone
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = B3
| pregnancy_AU_comment =<ref name="Esbriet PI" />
| pregnancy_category=
| routes_of_administration = [[경구 투여]]
| ATC_prefix = L04
| ATC_suffix = AX05

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment =<ref name="Esbriet PI">{{웹 인용|url=https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropesbrt11017 |title=Archived copy |access-date=8 January 2023 |archive-date=8 January 2023 |archive-url=https://web.archive.org/web/20230108233441/https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropesbrt11017 |url-status=live }}</ref><ref>{{웹 인용|url=https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropesbri10316 |title=Archived copy |access-date=8 January 2023 |archive-date=8 January 2023 |archive-url=https://web.archive.org/web/20230108233441/https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropesbri10316 |url-status=live }}</ref><ref>{{웹 인용| title=Prescription medicines: registration of new chemical entities in Australia, 2016 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016 | access-date=10 April 2023 | archive-date=10 April 2023 | archive-url=https://web.archive.org/web/20230410065503/https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2016 | url-status=live }}</ref>
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment =<ref name="CA Esbriet">{{웹 인용| title=Esbriet Product information | website=[[Health Canada]] | date=25 April 2012 | url=https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87895 | access-date=8 January 2023 | archive-date=8 January 2023 | archive-url=https://web.archive.org/web/20230108231249/https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=87895 | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =<ref name="Esbriet FDA label">{{웹 인용| title=Esbriet- pirfenidone capsule Esbriet- pirfenidone tablet, coated | website=DailyMed | date=14 December 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e | access-date=8 January 2023 | archive-date=8 January 2023 | archive-url=https://web.archive.org/web/20230108231246/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e | url-status=live }}</ref>
| legal_EU = Rx-only
| legal_EU_comment =<ref name="Esbriet EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_status      = Rx-only

<!-- Pharmacokinetic data -->
| protein_bound         = 50–58%<ref name = EMC>{{웹 인용|title=Esbriet 267 mg hard capsules|work=electronic Medicines Compendium|publisher=Intermune UK & I Ltd|date=3 January 2014|access-date=6 March 2014|url=http://www.medicines.org.uk/emc/medicine/26942/SPC/Esbriet+267+mg+hard+capsules/|archive-url=https://web.archive.org/web/20131012071615/http://medicines.org.uk/emc/medicine/26942/SPC/Esbriet+267+mg+hard+capsules/|archive-date=12 October 2013|url-status=dead}}</ref>
| metabolism            = [[간]] (70~80% [[CYP1A2]] 매개, 그 외 [[CYP2C9]], [[CYP2C19]], [[CYP2D6]], [[CYP2E1]]이 일부 기여)<ref name = EMC/>
| elimination_half-life = 2.4시간<ref name = EMC/>
| excretion             = [[소변]] (80%)<ref name = EMC/>

<!-- Identifiers -->
| CAS_number_Ref    =
| CAS_number =53179-13-8
| CAS_supplemental  =
| PubChem=40632
| IUPHAR_ligand     =
| DrugBank_Ref      =
| DrugBank          =
| ChemSpiderID_Ref  =
| ChemSpiderID = 37115
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = D7NLD2JX7U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01583
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 32016
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1256391
| NIAID_ChemDB      =
| PDB_ligand        =
| synonyms          =

<!--Chemical data-->
| IUPAC_name = 5-Methyl-1-phenylpyridin-2-one
| C=12 | H=11 | N=1 | O=1
| smiles = CC1=CN(C(=O)C=C1)C2=CC=CC=C2
| StdInChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
| StdInChIKey = ISWRGOKTTBVCFA-UHFFFAOYSA-N
| solubility = 10
| sol_units = mg/mL at 60 °C
}}

'''피르페니돈'''(pirfenidone)은 '''피레스파'''(Pirespa) 등의 상품명으로 판매되는 약물로, [[특발성 폐 섬유증]](IPF) 치료에 쓰인다. [[성장인자]], 그리고 [[프로콜라겐]] I과 II 생산을 하향조절해 [[폐섬유증]]을 감소시킨다.

2008년 일본에서 [[임상시험]]을 거쳐 최초로 특발성 폐 섬유증 환자에 대한 사용이 승인되었다. 유럽연합에서는 2011년,<ref name=Intermune>{{웹 인용| url = http://www.gene.com/patients/medicines/esbriet | title = InterMune: Pirfenidone | publisher = InterMune | access-date = 17 December 2015 | archive-date = 21 October 2020 | archive-url = https://web.archive.org/web/20201021191638/https://www.gene.com/patients/medicines/esbriet | url-status = live }}</ref><ref name="Esbriet EPAR">{{웹 인용| title=Esbriet EPAR | website=European Medicines Agency | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet | access-date=19 June 2020 | archive-date=24 November 2020 | archive-url=https://web.archive.org/web/20201124075320/https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet | url-status=live }}</ref> 캐나다에서는 2012년,<ref name="CA Esbriet" /> 미국에서는 2014년 10월 차례로 사용 허가가 났다.<ref name="Esbriet FDA label" /><ref name="FDA approval">{{웹 인용| title=Drug Approval Package: Esbriet (pirfenidone) Capsules NDA #022535 | website=U.S. Food and Drug Administration | date=24 December 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000toc.cfm | access-date=19 June 2020 | archive-date=3 January 2021 | archive-url=https://web.archive.org/web/20210103233725/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000toc.cfm | url-status=live }}</ref> 대한민국에서는 [[일동제약]]이 2011년 독점 판매 계약을 맺었고,<ref>{{웹 인용|url=http://www.doctorsnews.co.kr/news/articleView.html?idxno=71996|제목=일동제약, '피르페니돈' 국내 독점판매 계약|웹사이트=의협신문|성=이정환|날짜=2011-07-12|언어=ko|확인날짜=2024-06-05}}</ref> 2012년 사용 허가를 받았으며 2015년 10월부터 급여가 적용되었다.<ref>{{웹 인용|url=https://www.medipana.com/article/view.php?news_idx=195518&sch_menu=1&sch_gubun=5|제목=어렵게 '급여' 성공한 재수생 모아보니‥가혹한 기준|성=박으뜸|웹사이트=메디파나|날짜=2017-02-21|언어=ko|확인날짜=2024-06-05}}</ref>

[[복제약]]으로 이용 가능한 상태이다.<ref>{{웹 인용| title=2022 First Generic Drug Approvals | website=U.S. [[Food and Drug Administration]] (FDA) | date=3 March 2023 | url=https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-url=https://web.archive.org/web/20230630003602/https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/2022-first-generic-drug-approvals | archive-date=30 June 2023 | url-status=live | access-date=30 June 2023}}</ref>

== 각주 ==
{{각주}}

[[분류:호흡계통에 작용하는 약]]
[[분류:2-피리돈]]
[[분류:방향족 케톤]]
[[분류:희귀약]]